<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34284531</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1303-6165</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>SI-1</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>17</Day></PubDate></JournalIssue><Title>Turkish journal of medical sciences</Title><ISOAbbreviation>Turk J Med Sci</ISOAbbreviation></Journal><ArticleTitle>One and a half years into the COVID-19 pandemic - exit strategies and efficacy of SARS-CoV-2 vaccines for holistic management and achieving global control.</ArticleTitle><Pagination><StartPage>3157</StartPage><EndPage>3161</EndPage><MedlinePgn>3157-3161</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3906/sag-2106-236</ELocationID><Abstract><AbstractText>One and a half years into the pandemic, SARS-CoV-2 is still here to stay. Whilst rapid several effective COVID-19 vaccines have been developed and are being rolled out, the critical questions remain whether vaccines provide widespread protection against infection and reinfection, and what the duration of protection is. Community wide control cannot be obtained until almost everyone is immune. Vaccine production must be ramped up to cover the world population. The price of herd immunity through natural infection is high mortality in the elderly and morbidity in other age groups including children and Long-COVID. We must expect a new wave in the coming winter. The severity will depend on the proportion of the population with immunity from natural infections or immunisation. Therefore, control rests on a population wide immunisation including children, which may or may not need to be repeated if new SARS-CoV-2 variants evolve that can escape immunity from either previous infections or immunisations. Preventing long term sequelae of COVID-19 also remains a priority.</AbstractText><CopyrightInformation>This work is licensed under a Creative Commons Attribution 4.0 International License.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Eskild</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8793-9680</Identifier><AffiliationInfo><Affiliation>European Society for Clinical Microbiology and Infectious Diseases, Emerging Infections Task Force, ESCMID, Basel, Switzerland</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical Medicine, Aarhus University, Denmark</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;kengin</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1845-5284</Identifier><AffiliationInfo><Affiliation>Depatmernt of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, &#x130;zmir, Turkey</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Balushi</LastName><ForeName>Asma</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9836-4368</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases Department, Internal Medicine, Sohar Hospital, Oman</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zumla</LastName><ForeName>Alimuddin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5111-5735</Identifier><AffiliationInfo><Affiliation>Division of Infection and Immunity, Center for Clinical Microbiology, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk J Med Sci</MedlineTA><NlmUniqueID>9441758</NlmUniqueID><ISSNLinking>1300-0144</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword><Keyword MajorTopicYN="N">surveillance</Keyword><Keyword MajorTopicYN="N">variants</Keyword><Keyword MajorTopicYN="N">zoonosis</Keyword></KeywordList><CoiStatement>none declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>21</Day><Hour>2</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34284531</ArticleId><ArticleId IdType="pmc">PMC8771007</ArticleId><ArticleId IdType="doi">10.3906/sag-2106-236</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fontanet A Cauchemez S. COVID -19 herd immunity: where are we. Nature Reviews of Immunology. 2020;20:583&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7480627</ArticleId><ArticleId IdType="pubmed">32908300</ArticleId></ArticleIdList></Reference><Reference><Citation>-19 reinfections in The Gambia by phylogenetically distinct SARS-CoV-2 variants&#x2014;first two confirmed events in west Africa. The Lancet Global Health 3 June. 2021. pp. S2214&#x2013;S2214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8175042</ArticleId><ArticleId IdType="pubmed">34090610</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadas SM Fitzpatrick MC Sah P &#xa0;Pandey A Shoukat A et al. Proceedings of the National Academy of Science USA. 2020;117:17513&#x2013;17515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7395516</ArticleId><ArticleId IdType="pubmed">32632012</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen E Koopmans M Go U Hamer DH Petrosillo N Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infectious Diseases. 2020;20:e238&#x2013;e244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333991</ArticleId><ArticleId IdType="pubmed">32628905</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen E Buchy P Vaccination against SARS-CoV-2 should be included in childhood vaccination programs. International Journal of Infectious Diseases. 2021;106:429&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084275</ArticleId><ArticleId IdType="pubmed">33933590</ArticleId></ArticleIdList></Reference><Reference><Citation>Piroth L Cottenet J Mariet A-S Bonniaud P Blot M Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respiratory Medicine. 2020;9:251&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832247</ArticleId><ArticleId IdType="pubmed">33341155</ArticleId></ArticleIdList></Reference><Reference><Citation>Geers D Shamier MC Bogers S den Hartog G Gommers L SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccines. Science Immunology. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9268159</ArticleId><ArticleId IdType="pubmed">34035118</ArticleId></ArticleIdList></Reference><Reference><Citation>Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nature Medicine 2021 10th June. doi: 10.1038/s41591-021-01407-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34113015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissler SM Tedijanto C Goldstein E Grad YH Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368:860&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164482</ArticleId><ArticleId IdType="pubmed">32291278</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavine JS Bjornstad ON Antia R Immunological characteristics govern the transition of COVID-19 to endemicity. Science. 2021;371:741&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7932103</ArticleId><ArticleId IdType="pubmed">33436525</ArticleId></ArticleIdList></Reference><Reference><Citation>mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nature Medicine 2021 July 9th. doi: 10.</Citation><ArticleIdList><ArticleId IdType="pubmed">34244681</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MG Burgess JL Naleway AL Prevention and attenuation of Covid-19 with the BNT162b2. N Engl J Med. 2021;1273:320&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262622</ArticleId><ArticleId IdType="pubmed">34192428</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MG Burgess JL Naleway AL Interim estimates of vaccine effectiveness of BNT162b2 and mRNA- MMWR Morb Mortal Wkly Rep. 2021;70:495&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8022879</ArticleId><ArticleId IdType="pubmed">33793460</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanriover MD Doganay HL Akova M Azap A E&#xf0;cacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet 2021 July 8. 6736:01429&#x2013;01429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8266301</ArticleId><ArticleId IdType="pubmed">34246358</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara A Undurraga EA Gonz&#xe1;lez C Paredes F Fontecilla F 7th July. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. New England Journal of Medicine. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279092</ArticleId><ArticleId IdType="pubmed">34233097</ArticleId></ArticleIdList></Reference><Reference><Citation>Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617. 2021. pp. 1167&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389394</ArticleId><ArticleId IdType="pubmed">34437521</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan AL Eccleston-Turney M Rourke M Maleche A Wang C Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access. Lancet. 2020;396:800&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832682</ArticleId><ArticleId IdType="pubmed">32910908</ArticleId></ArticleIdList></Reference><Reference><Citation>Fidler DP Negotiating equitable access to influenza vaccines: global health diplomacy and the controversies surrounding avian influenza H5N1 and pandemic influenza H1N1. PLoS Medicine. 2010;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864298</ArticleId><ArticleId IdType="pubmed">20454566</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo JC Ahuja A Athey S Baker A Budish E Market design to accelerate COVID-19 vaccine supply. Science. 2021;371:1107&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">33632897</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwabenland M Sali&#xe9; H Tanevski J Killmer S Lago MS Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T cell interactions. Cell. 2021;06</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8188302</ArticleId><ArticleId IdType="pubmed">34174183</ArticleId></ArticleIdList></Reference><Reference><Citation>Infection, recovery and re-infection of farmed mink with SARS-CoV-2. bioRxiv preprint 7 May. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629378</ArticleId><ArticleId IdType="pubmed">34780574</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopmans MK SARS-CoV-2 and the human-animal interface: outbreaks on mink farms. Lancet Infectious Diseases. 2021;21:18&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832374</ArticleId><ArticleId IdType="pubmed">33227234</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X Newman C Buesching CD Macdonald DW Zhou Z Animal sales from Wuhan wet markets immediately prior to the COVID-19 pandemic. Science Reports. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184983</ArticleId><ArticleId IdType="pubmed">34099828</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer SM Burke DS Historical perspective--Emergence of influenza A (H1N1) viruses. New England Journal of Medicine. 2009;361:279&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">19564632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>